GlobeStar Therapeutics Corporation Awards New York Bay Capital, LLC Investment Banking Contract
GlobeStar Therapeutics Corporation (OTCQB:GSTC) has appointed New York Bay Capital, LLC as its financial advisor and private placement agent. This strategic move aims to attract accredited investors under SEC guidelines, facilitating clinical trials for its patented solution targeting neuromuscular diseases, including Muscular Dystrophy. The CEO, James C. Katzaroff, emphasized the significance of this partnership in progressing toward impactful treatments for chronic conditions like Multiple Sclerosis.
- Appointment of New York Bay Capital as financial advisor may enhance fundraising efforts.
- Focus on neuromuscular diseases positions GlobeStar as a dedicated player in healthcare innovation.
- None.
Agency selected because of performance history and a deep understanding of the company's healthcare, technology, and lifestyle spaces.
RICHLAND, WA / ACCESSWIRE / March 1, 2022 / GlobeStar Therapeutics Corporation (OTCQB:GSTC) (www.globestarthera.com) headquartered in Richland, Washington, is a fast-growing company focused on providing medical research, development, and treatments for disease. The company is pleased to announce New York Bay Capital, LLC as their cross-border and U.S. financial advisor and private placement agents focused solely on qualifying accredited investors recognized under the registration exemptions provided for under relevant SEC requirements and related rules and regulations."
Selecting New York Bay Capital, LLC is a significant step forward for GlobeStar Therapeutics," said James C. Katzaroff, President and CEO, GlobeStar Therapeutics Corporation. "GlobeStar has made tremendous progress toward our goal of running a clinical trial on our patented solution. This is the next step in the process toward helping millions with neuromuscular disease around the globe."GlobeStar's patented solution has the potential to change the lives of millions of Muscular Dystrophy patients across the globe.
This life-changing neurodegenerative disease is at the forefront of the CDC and FDA's radar. The entire GlobeStar Therapeutics team understands the importance of meeting the challenges associated with Multiple Sclerosis and other life-changing neurodegenerative diseases.
GlobeStar Therapeutics Corporation.
GlobeStar Therapeutics Corporation (OTCQB:GSTC) is a healthcare company dedicated to bringing innovative, effective, and high-quality healthcare solutions to the medical community. With a focus on Multiple Sclerosis and other chronic diseases, GlobeStar's team is committed to helping those suffering begin their journey back to health. More information about GlobeStar Therapeutics Corporation can be found at www.globestarthera.com.
Notice Regarding Forward Looking StatementsThis news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements that include the words "believes," "expects," "anticipate" or similar expressions. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Media Contact:
Brooke Greenwald
Cornerstone Communications, LTD
brooke@cornerstonepr.net
(240) 370-0866
SOURCE: GlobeStar Therapeutics Corporation
View source version on accesswire.com:
https://www.accesswire.com/690896/GlobeStar-Therapeutics-Corporation-Awards-New-York-Bay-Capital-LLC-Investment-Banking-Contract
FAQ
What is the recent partnership announced by GlobeStar Therapeutics?
How will the partnership with New York Bay Capital benefit GlobeStar Therapeutics?
What diseases is GlobeStar Therapeutics focusing on?
What is the significance of GlobeStar's clinical trials?
What is the stock symbol for GlobeStar Therapeutics Corporation?
